Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(19)30019-1
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

PARP Inhibitors in Ovarian Cancer

2013English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

The Development of PARP Inhibitors in Ovarian Cancer: From Bench to Bedside

British Journal of Cancer
Cancer ResearchOncology
2015English

PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers

Clinical Cancer Research
Cancer ResearchOncology
2019English

Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2017English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions

British Journal of Cancer
Cancer ResearchOncology
2016English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy